Academic Journal
Anti-cancer efficacy of combined vaccine-strain measles and mumps viruses against colorectal cancer: an experimental study.
| Τίτλος: | Anti-cancer efficacy of combined vaccine-strain measles and mumps viruses against colorectal cancer: an experimental study. |
|---|---|
| Συγγραφείς: | Hung TX; Department of Gastrointestinal Endoscopy, 108 Military Central Hospital; 1st Tran Hung Dao Street, Hai Ba Trung Ward, Hanoi City, Vietnam., Tung ND; Department of Quality Management, 108 Military Central Hospital; 1st Tran Hung Dao Street, Hai Ba Trung Ward, Hanoi City, Vietnam., Huong NT; Department of Hepatobiliary, 108 Military Central Hospital, 1st Tran Hung Dao Street, Hai Ba Trung Ward, Hanoi City, Vietnam., Hoa DT; Department of Experimental Medicine, 108 Military Central Hospital; 1st Tran Hung Dao Street, Hai Ba Trung Ward, Hanoi City, Vietnam., Cuong LD; Department of Experimental Medicine, 108 Military Central Hospital; 1st Tran Hung Dao Street, Hai Ba Trung Ward, Hanoi City, Vietnam. leduycuong76@gmail.com. |
| Πηγή: | Molecular biology reports [Mol Biol Rep] 2026 Sep 05; Vol. 53 (1). Date of Electronic Publication: 2026 Sep 05. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Reidel Country of Publication: Netherlands NLM ID: 0403234 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-4978 (Electronic) Linking ISSN: 03014851 NLM ISO Abbreviation: Mol Biol Rep Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Dordrecht, Boston, Reidel. |
| Ιατρικοί όροι (MeSH): | Colorectal Neoplasms*/therapy , Colorectal Neoplasms*/virology , Measles virus*/immunology , Mumps virus*/immunology , Oncolytic Virotherapy*/methods, Animals ; Humans ; Mice ; Mice, Nude ; Xenograft Model Antitumor Assays ; Apoptosis ; HT29 Cells ; Cell Survival ; Cell Line, Tumor ; Oncolytic Viruses ; Mice, Inbred BALB C |
| Περίληψη: | Objectives: This study aimed to evaluate the oncolytic efficacy of a combination of vaccine-strain measles virus (MeV) and mumps virus (MuV) against colorectal cancer (CRC) cells in vitro and in a nude mouse xenograft model. Materials and Methods: HT-29 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) and infected with MeV, MuV, or a combination of MeV and MuV (MM; MeV: MuV = 1:1, v/v). Cell viability, synergistic effects, and apoptosis were assessed using MTT and flow cytometry assays, respectively, in vitro. A nude mouse xenograft model was established to evaluate the in vivo oncolytic efficacy of the MM against CRC xenograft tumors. Results: The MM demonstrated synergistic effects at 48, 72, and 96 h (CI = 0.473, 0.692, and 0.633, respectively). The MM-treated group showed significantly lower cell viability (p < 0.05) and a markedly higher apoptotic rate (p < 0.01) compared with single-virus-infected groups in vitro. In the xenograft model, the MM-treated group exhibited significantly slower tumor growth (p ≤ 0.001), significantly prolonged survival (p < 0.05), reduced mortality, and increased proportions of innate immune cell populations in the spleen compared with single-virus-treated groups. Conclusions: The MM demonstrated synergistic and superior oncolytic efficacy against HT-29 colorectal cancer cells compared with single-virus therapies in both in vitro and in vivo xenograft models. (© 2026. The Author(s), under exclusive licence to Springer Nature B.V.) |
| Competing Interests: | Declarations. Conflict of interest: All Authors have no conflicts of interest to declare. |
| References: | Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11579-11584. (PMID: 27671656) Cancer Immunol Res. 2014 Apr;2(4):295-300. (PMID: 24764576) Viruses. 2016 Sep 20;8(9):. (PMID: 27657109) Hum Gene Ther. 2012 Mar;23(3):295-301. (PMID: 22235810) Cancer Invest. 2018 Feb 7;36(2):106-117. (PMID: 29485292) PLoS One. 2023 Dec 13;18(12):e0295819. (PMID: 38091318) Br J Cancer. 2010 May 25;102(11):1555-77. (PMID: 20502460) Oncol Rep. 2013 Jan;29(1):199-204. (PMID: 23129111) Immunotherapy. 2010 Mar;2(2):185-99. (PMID: 20635927) Gut Liver. 2013 Nov;7(6):629-41. (PMID: 24312702) PLoS Pathog. 2010 Jun 24;6(6):e1000973. (PMID: 20585633) CA Cancer J Clin. 2024 May-Jun;74(3):229-263. (PMID: 38572751) Viruses. 2014 Jun 02;6(6):2268-86. (PMID: 24892636) Cancer Res. 2004 Jul 15;64(14):4919-26. (PMID: 15256464) Biomed Res Int. 2013;2013:387362. (PMID: 23586034) Curr Clin Microbiol Rep. 2016 Sep;3(3):142-154. (PMID: 28138419) Oncotarget. 2015 Jun 30;6(18):16019-30. (PMID: 25909216) Sci Rep. 2016 Apr 19;6:24572. (PMID: 27090874) Cancer Gene Ther. 2005 Jul;12(7):593-9. (PMID: 15746945) J Cell Mol Med. 2013 Sep;17(9):1088-95. (PMID: 24151976) Adv Enzyme Regul. 1984;22:27-55. (PMID: 6382953) PLoS One. 2011 Apr 14;6(4):e18765. (PMID: 21533140) Eur J Pharmacol. 2021 Apr 15;897:173919. (PMID: 33577837) Gene Ther. 2013 Apr;20(4):444-9. (PMID: 22914495) Cell Death Dis. 2013 May 16;4:e631. (PMID: 23681226) Viruses. 2015 Oct 26;7(10):5610-8. (PMID: 26516901) Saudi J Biol Sci. 2020 Mar;27(3):865-872. (PMID: 32127764) Mol Ther. 2010 May;18(5):888-95. (PMID: 20234341) Front Immunol. 2016 Jan 14;6:663. (PMID: 26834740) J Immunol. 2004 Feb 1;172(3):1455-62. (PMID: 14734722) Mol Ther. 2009 Dec;17(12):2041-8. (PMID: 19773744) Hepatology. 2006 Dec;44(6):1465-77. (PMID: 17133484) Anticancer Res. 2019 Jul;39(7):3727-3737. (PMID: 31262899) Cancer Res. 2007 Nov 15;67(22):10939-47. (PMID: 18006839) J Biosci. 2019 Mar;44(1):. (PMID: 30837361) Cancer Res. 2002 Aug 15;62(16):4656-62. (PMID: 12183422) Cancer Lett. 2014 Nov 28;354(2):272-80. (PMID: 25193462) Virol J. 2011 May 13;8:224. (PMID: 21569530) |
| Contributed Indexing: | Keywords: HT-29 cells; Measles vius; colorectal cancer; mumps virus; oncolytic virotherapy |
| Entry Date(s): | Date Created: 20260905 Date Completed: 20260905 Latest Revision: 20261008 |
| Update Code: | 20261008 |
| DOI: | 10.1007/s11033-026-12724-8 |
| PMID: | 42700211 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1573-4978 |
|---|---|
| DOI: | 10.1007/s11033-026-12724-8 |